home / stock / blph / blph news

BLPH News and Press, Bellerophon Therapeutics Inc. From 08/01/19

Stock Information
Company Name: Bellerophon Therapeutics Inc.
Stock Symbol: BLPH
Market: OTC
Website: bellerophon.com
Menu
BLPH BLPH Quote BLPH Short BLPH News BLPH Articles BLPH Message Board
Get BLPH Alerts

News, Short Squeeze, Breakout and More Instantly...
BLPH - Bellerophon Completes Enrollment in Cohort 2 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

WARREN, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it has completed enrollment for Cohort 2 of its ongoing Phase 2/3 random...
BLPH - Bellerophon to Present at the JMP Securities Life Sciences Conference

WARREN, N.J., June 13, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today that Fabian Tenenbaum, Chief Executive Officer, will present a corporate over...

BLPH - Bellerophon to Host Key Opinion Leader Meeting Focused on Pulmonary Hypertension Associated with Interstitial Lung Disease

WARREN, N.J., May 22, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it will host a Key Opinion Leader (KOL) lunch meeting focused on Pulmonar...

BLPH - Bellerophon Presents Additional Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference

WARREN, N.J., May 21, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, presented additional data from Cohort 1 of its ongoing Phase 2/3 randomized, double-blind, pla...
BLPH - Bellerophon to Present Additional Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference

Results to be Presented in Late-Breaking Abstract as an Oral Presentation Company will Also Present a Corporate Overview and Update on its PH-ILD Program at Respiratory Innovation Summit WARREN, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (&#...

BLPH - Bellerophon Therapeutics beats by $0.09

Bellerophon Therapeutics (NASDAQ: BLPH ): Q1 GAAP EPS of -$0.01 beats by $0.09 . More news on: Bellerophon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

BLPH - Bellerophon Provides Business Update and Reports First Quarter 2019 Financial Results

WARREN, N.J., May 09, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the first quarter ended Ma...
BLPH - Bellerophon Announces Agreement with FDA on Regulatory Approval Pathway for INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

FDA Agrees to Primary Endpoint of Change in Moderate to Vigorous Physical Activity from Baseline to Week 16, Measured by Actigraphy FDA Also Agrees on Modification of Ongoing Phase 2b Study into a Phase 2/3 Trial, with Cohort 3 Serving as the Pivotal Phase 3 Study Completion of Co...

BLPH - Bellerophon Therapeutics beats by $0.11

Bellerophon Therapeutics (NASDAQ: BLPH ): Q4 GAAP EPS of -$0.02  beats by $0.11 . More news on: Bellerophon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

BLPH - Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2018 Financial Results

WARREN, N.J., March 14, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the fourth quarter and y...
Previous 10 Next 10